Gingko mihuanAlternative Names: Gingko Mihuan - Tianyin Pharmaceuticals; Gingko Mihuan - TPI; GMOL
Latest Information Update: 29 Dec 2014
At a glance
- Originator Tianyin Pharmaceutical
- Class Cardiovascular therapies; Flavonoids; Glycosides; Terpenes; Traditional-Chinese-medicine
- Mechanism of Action Antioxidants; Platelet activating factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Angina pectoris; Cardiovascular disorders; Cerebral infarction; Cerebral ischaemia; Coronary disorders; Memory disorders; Neurological disorders; Stroke